These authors point out that the mechanisms of resistance to NRG1-targeting agents could be potentially explained by the upregulation of NRG1 as well as parallel pathway activation, as seen in HER2-positive breast cancer models and ALK-positive lung cancer [29]. Here, ERBB2 is linked to breast carcinoma.